Biomica pushes the barriers by addressing the root cause of the disorder

Immuno-oncology

Recent evidence underscores the role of the microbiome in cancer therapy response, particularly in its impact on immune checkpoint inhibitors like PD-1/PD-L1. As research unfolds, it becomes increasingly apparent that modulating the intestinal microbiome could serve as a novel and effective adjunct mean to augment current anti-cancer treatments.

  • Program
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approach

BMC128

Combination Therapy with ICI for Solid Tumors

  • Program
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Approach

Biological

Harnessing our computational analysis and predictive capabilities, we have identified BMC128, a rationally designed microbial consortium.

Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.

Antimicrobial Resistance (AMR)

  • Program
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Approach

BMC202

C difficile Infection

  • Program
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Approach

Small-molecule

Antibiotic-Resistant Bacteria: Clostridioides difficile Infection (CDI)— Is a pervasive hospital-acquired infection posing a significant public health threat, with an annual economic toll of $5.4 billion in the US alone.

Utilizing our microbiome therapeutics platform, we’re advancing BMC201—a small-molecule drug candidate designed to combat the primary toxin produced by Clostridioidesdifficile. BMC201 is formulated for oral administration, with our therapeutic strategy aimed at mitigating dysbiosis in the colonic microbiome amid recurrent CDI.

By specifically targeting the toxin secreted by Clostridioides difficile, we develop a highly selective treatment option designed to alleviate CDI-related symptoms. Unlike conventional antibiotic therapies, our approach preserves the patient’s vital commensal intestinal microbial community.

BMC230

MRSA Infection

  • Program
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
Approach

Small-molecule

MRSA, a multi-drug resistant bacterium, responsible for several difficult-to-treat infections in humans, leading to tens of thousands of annual cases of mortality in the US.
Biomica is engaged in a collaboration with Prof. Ada Yonath’s, Nobel Prize laureate, at the Weizmann Institute of Science in Israel to develop a selective treatment against antibiotic resistant strains of Staphylococcus aureus infection, in a microbiome focused approach.